Alphamab Oncology (STU:3NK) EBIT : €-26.29 Mil (TTM As of Jun. 2024)

Alphamab Oncology EBIT Chart

Alphamab Oncology Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
EBIT	Get a 7-Day Free Trial									-19.28	-23.71	-4.24	-21.26	-5.04

Competitive Comparison of Alphamab Oncology's EBIT

For the Biotechnology subindustry, Alphamab Oncology's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alphamab Oncology's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alphamab Oncology's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Alphamab Oncology's EV-to-EBIT falls into.

Alphamab Oncology EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-26.29 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alphamab Oncology  (STU:3NK) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Alphamab Oncology's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

where

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Alphamab Oncology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

where Working Capital is:

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Alphamab Oncology's Earnings Yield (Joel Greenblatt) % for today is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alphamab Oncology EBIT Related Terms

Thank you for viewing the detailed overview of Alphamab Oncology's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Alphamab Oncology Business Description